In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Novo Nordisk’s diabetes pill Rybelsus, an oral semaglutide, reduced the risk of major heart-related events by 14% in adults with Type 2 diabetes and cardiovascular disease or chronic kidney disease, ...

Novo Nordisk’s diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

A recent study highlights the effectiveness of Semaglutide, an anti-diabetes drug, in reducing the risk of heart attacks and ...